DK1448562T3 - Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer - Google Patents

Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer

Info

Publication number
DK1448562T3
DK1448562T3 DK02782289T DK02782289T DK1448562T3 DK 1448562 T3 DK1448562 T3 DK 1448562T3 DK 02782289 T DK02782289 T DK 02782289T DK 02782289 T DK02782289 T DK 02782289T DK 1448562 T3 DK1448562 T3 DK 1448562T3
Authority
DK
Denmark
Prior art keywords
phosphodiesterase inhibitors
derivatives useful
substituted tetracyclic
pyrroloquinolone derivatives
tetracyclic pyrroloquinolone
Prior art date
Application number
DK02782289T
Other languages
Danish (da)
English (en)
Inventor
Weiqin Jiang
Zhihua Sui
Original Assignee
Ortho Mcneil Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharmaceutical Co filed Critical Ortho Mcneil Pharmaceutical Co
Application granted granted Critical
Publication of DK1448562T3 publication Critical patent/DK1448562T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
DK02782289T 2001-11-14 2002-11-12 Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer DK1448562T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33297701P 2001-11-14 2001-11-14
PCT/US2002/036117 WO2003042213A1 (fr) 2001-11-14 2002-11-12 Derives tetracycliques substitues de pyrroloquinolone utiles en tant qu'inhibiteurs de phosphodiesterase

Publications (1)

Publication Number Publication Date
DK1448562T3 true DK1448562T3 (da) 2007-09-24

Family

ID=23300709

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02782289T DK1448562T3 (da) 2001-11-14 2002-11-12 Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer

Country Status (15)

Country Link
US (1) US6686349B2 (fr)
EP (1) EP1448562B1 (fr)
JP (1) JP4484517B2 (fr)
CN (1) CN1280292C (fr)
AT (1) ATE368040T1 (fr)
CA (1) CA2467269C (fr)
CY (1) CY1107747T1 (fr)
DE (1) DE60221425T2 (fr)
DK (1) DK1448562T3 (fr)
ES (1) ES2289159T3 (fr)
HK (1) HK1069169A1 (fr)
MY (1) MY128241A (fr)
PT (1) PT1448562E (fr)
TW (1) TWI264437B (fr)
WO (1) WO2003042213A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629299A1 (de) * 1996-07-20 1998-01-22 Agfa Gevaert Ag Verfahren und Vorrichtung zum Aufnehmen einer Bildinformation
DE60317684T4 (de) * 2002-06-19 2011-06-22 Janssen Pharmaceutica N.V., 2340 SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651862A1 (fr) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
WO2008036678A2 (fr) * 2006-09-19 2008-03-27 Braincells, Inc. Modulation induite par ppar de la neurogenèse
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1914235A1 (fr) * 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Dérivés chirales tetra-hydro beta-carbolines en tant qu'agents antiparasitaires
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
CN110862391B (zh) * 2019-11-13 2020-09-25 株洲千金药业股份有限公司 一种他达拉非杂质g的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH625521A5 (fr) 1976-10-15 1981-09-30 Sandoz Ag
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази

Also Published As

Publication number Publication date
CN1615309A (zh) 2005-05-11
CN1280292C (zh) 2006-10-18
US20030144268A1 (en) 2003-07-31
DE60221425D1 (de) 2007-09-06
ATE368040T1 (de) 2007-08-15
ES2289159T3 (es) 2008-02-01
MY128241A (en) 2007-01-31
HK1069169A1 (en) 2005-05-13
CA2467269C (fr) 2011-04-05
US6686349B2 (en) 2004-02-03
WO2003042213A1 (fr) 2003-05-22
CA2467269A1 (fr) 2003-05-22
TWI264437B (en) 2006-10-21
EP1448562B1 (fr) 2007-07-25
DE60221425T2 (de) 2008-06-26
JP4484517B2 (ja) 2010-06-16
JP2005511626A (ja) 2005-04-28
PT1448562E (pt) 2007-08-31
EP1448562A1 (fr) 2004-08-25
TW200408640A (en) 2004-06-01
CY1107747T1 (el) 2013-04-18

Similar Documents

Publication Publication Date Title
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MXPA02011425A (es) Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa.
EA200700099A1 (ru) Производные пиридина
ATE433447T1 (de) Pyrimiidinverbindungen
ATE301653T1 (de) Pyrazolopyridine
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
AU2003228770A8 (en) Substituted pyrazolopyrimidines
CY1107196T1 (el) Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
ATE300541T1 (de) Pyrazolopyridinderivate
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
NO20033959D0 (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
TW200628153A (en) Novel compounds
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE274515T1 (de) Pyrazolopyridinderivate
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel